WILLIAM A. KINNEY, PHD \u2013 CHIEF SCIENTIFIC OFFICER<\/strong><\/h3>\nDr. Kinney is a medicinal chemist and entrepreneur with greater than 25 years of experience in large pharmaceutical (Wyeth, Johnson & Johnson), biotechnology (Magainin), and non-profit (Blumberg Institute) research and development. He has demonstrated expertise in drug design; synthesis; lead optimization of peptides, small molecules, and natural products<\/span>; and is inventor of three molecules that advanced to human clinical trials \u2013 Perzinfotel (CNS disorders and pain), Squalamine (oncology and AMD), and Trodusquemine (obesity).<\/span><\/p>\nCurrently, Dr. Kinney is Director of the Natural Product Discovery Institute and Chief Scientific Officer at KannaLife Sciences. His scientific contributions include more than 70 publications and presentations; and inventorship on 38 issued U.S. patents.<\/span><\/p>\nDr. Kinney is a co-inventor of Kannalife\u2019s recent US Patent #9611213 \u201cNovel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy.\u201d<\/span><\/p>\n<\/div>\n<\/div>\n[\/et_pb_text][et_pb_image src=”https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2021\/09\/William_Kinney.jpg” title_text=”William_Kinney” align=”center” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
\n\nMARK CORRAO \u2013 CHIEF FINANCIAL OFFICER<\/strong><\/h3>\nMr. Corrao was formerly a founder and CFO of Strikeforce Technologies, Inc., a publicly traded software development and services company specializing in the development of a suite of integrated computer network security<\/span>. In addition to the ten years of his service at Strikeforce, Mr. Corrao has spent numerous years in the public accounting arena specializing in certified auditing, SEC accounting, corporate taxation and financial planning. Mr. Corrao\u2019s background also includes numerous years on Wall Street with Merrill Lynch, Spear Leeds & Kellogg and Greenfield Arbitrage Partners. While on Wall Street Mr. Corrao was involved in several IPO\u2019s and has been a guiding influence in several start up companies. Prior to joining StrikeForce, he was the Director of Sales at Applied Digital Solutions from December 2000 through December 2001. Mr. Corrao was the Vice President of Sales at Advanced Communications Sciences from March 1997 though December 2000. Mr. Corrao has a B.S. from CUNY.<\/span><\/p>\n<\/div>\n<\/div>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” custom_padding=”2px||3px|||” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” background_color=”#21b494″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” header_2_font=”|800|||||||” header_2_text_color=”#FFFFFF” header_2_font_size=”34px” global_colors_info=”{}”]<\/p>\n
AREAS OF FOCUS<\/h2>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2021\/09\/kannalife-areas-of-focus.jpg” title_text=”kannalife-areas-of-focus” align=”center” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Kannalife\u2122 Sciences is currently researching cannabinoids, specifically CBD, to understand how they can be utilized in the development of novel treatments for a range of neurodegenerative diseases, including hepatic encephalopathy, chronic traumatic encephalopathy, and chemotherapy induced peripheral neuropathy. They have created the synthetic cannabinoid, KLS-13019, which is 50 times more potent and 400 times less toxic than naturally occurring cannabidiol, in the hopes of using it in the development of safe and effective new treatments for a range of neurological conditions.<\/span><\/p>\nHEPATIC ENCEPHALOPATHY<\/strong><\/h3>\nHepatic encephalopathy (HE) is a condition in which the liver can no longer remove toxins from the blood, resulting in a loss of brain function. HE is sometimes the result of hepatitis or the abuse of alcohol or painkillers. When the liver cannot adequately protect the body, toxins like ammonia can build up in the bloodstream, causing damage to the brain and nervous system.\u00a0<\/span><\/p>\nKannalife\u2122 Sciences is exploring ways to use the neuroprotective properties of cannabinoids to help combat this brain damage. Although HE is considered a rare disease with fewer than 200,000 yearly cases, the cost to treat it in the U.S. alone is estimated up to\u00a0<\/span>$7 billion per year<\/span><\/a>.<\/span><\/p>\nCHRONIC TRAUMATIC ENCEPHALOPATHY<\/strong><\/h3>\nSimilarly, Kannalife\u2122 is developing cannabinoid based treatments for chronic traumatic encephalopathy (CTE). Caused by repeated injuries to the head, CTE is linked to contact sports and has been especially prevalent among NFL players and women\u2019s soccer players. During head injuries, nerve axons become damaged, hindering cell-to-cell communication and causing the cells in the brain to waste away.\u00a0<\/span><\/p>\nCannabinoids can be used to reduce the oxidative stress following head injuries and reduce the swelling that results in the brain. Currently, CTE can only be diagnosed in post-mortem examinations of the brain, making it difficult to determine a population of CTE sufferers. Studies showed the overall prevalence of CTE in football players at\u00a0<\/span>3.7%<\/span><\/a>\u00a0of the total population. Kannalife\u2122 is exploring preventative as well as post-diagnosis solutions for CTE based on cannabinoids.\u00a0<\/span><\/p>\nCHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY<\/strong><\/h3>\nThe company\u2019s newest efforts are aimed at developing a treatment for chemotherapy induced peripheral neuropathy (CIPN). CIPN occurs because chemotherapy and other cancer treatments can cause damage to the nerves away from the brain and spinal cord, with symptoms including tingling in the extremities, burning pain, decreased sensation, and increased sensitivity to touch, temperature, and more. In some cases, nerve damage can be permanent.\u00a0<\/span><\/p>\nNo medication or supplement has been shown to definitively prevent CIPN, and it can be disabling side effect of cancer treatment. The global market for the treatment of symptoms associated with CIPN is expected to hit\u00a0<\/span>$1.88 bill by 2024<\/span><\/a>. Kannalife is targeting clinical trials for KLS-13019, its proprietary CBD-like molecule, as a therapeutic for CIPN to begin in Q2 2020.<\/span><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” custom_padding=”2px||3px|||” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” background_color=”#21b494″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” header_2_font=”|800|||||||” header_2_text_color=”#FFFFFF” header_2_font_size=”34px” global_colors_info=”{}”]<\/p>\n
CONTACT<\/h2>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
Our Website:<\/span><\/p>\n
Currently, Dr. Kinney is Director of the Natural Product Discovery Institute and Chief Scientific Officer at KannaLife Sciences. His scientific contributions include more than 70 publications and presentations; and inventorship on 38 issued U.S. patents.<\/span><\/p>\n Dr. Kinney is a co-inventor of Kannalife\u2019s recent US Patent #9611213 \u201cNovel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy.\u201d<\/span><\/p>\n<\/div>\n<\/div>\n [\/et_pb_text][et_pb_image src=”https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2021\/09\/William_Kinney.jpg” title_text=”William_Kinney” align=”center” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n Mr. Corrao was formerly a founder and CFO of Strikeforce Technologies, Inc., a publicly traded software development and services company specializing in the development of a suite of integrated computer network security<\/span>. In addition to the ten years of his service at Strikeforce, Mr. Corrao has spent numerous years in the public accounting arena specializing in certified auditing, SEC accounting, corporate taxation and financial planning. Mr. Corrao\u2019s background also includes numerous years on Wall Street with Merrill Lynch, Spear Leeds & Kellogg and Greenfield Arbitrage Partners. While on Wall Street Mr. Corrao was involved in several IPO\u2019s and has been a guiding influence in several start up companies. Prior to joining StrikeForce, he was the Director of Sales at Applied Digital Solutions from December 2000 through December 2001. Mr. Corrao was the Vice President of Sales at Advanced Communications Sciences from March 1997 though December 2000. Mr. Corrao has a B.S. from CUNY.<\/span><\/p>\n<\/div>\n<\/div>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” custom_padding=”2px||3px|||” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” background_color=”#21b494″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” header_2_font=”|800|||||||” header_2_text_color=”#FFFFFF” header_2_font_size=”34px” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2021\/09\/kannalife-areas-of-focus.jpg” title_text=”kannalife-areas-of-focus” align=”center” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n Kannalife\u2122 Sciences is currently researching cannabinoids, specifically CBD, to understand how they can be utilized in the development of novel treatments for a range of neurodegenerative diseases, including hepatic encephalopathy, chronic traumatic encephalopathy, and chemotherapy induced peripheral neuropathy. They have created the synthetic cannabinoid, KLS-13019, which is 50 times more potent and 400 times less toxic than naturally occurring cannabidiol, in the hopes of using it in the development of safe and effective new treatments for a range of neurological conditions.<\/span><\/p>\n Hepatic encephalopathy (HE) is a condition in which the liver can no longer remove toxins from the blood, resulting in a loss of brain function. HE is sometimes the result of hepatitis or the abuse of alcohol or painkillers. When the liver cannot adequately protect the body, toxins like ammonia can build up in the bloodstream, causing damage to the brain and nervous system.\u00a0<\/span><\/p>\n Kannalife\u2122 Sciences is exploring ways to use the neuroprotective properties of cannabinoids to help combat this brain damage. Although HE is considered a rare disease with fewer than 200,000 yearly cases, the cost to treat it in the U.S. alone is estimated up to\u00a0<\/span>$7 billion per year<\/span><\/a>.<\/span><\/p>\n Similarly, Kannalife\u2122 is developing cannabinoid based treatments for chronic traumatic encephalopathy (CTE). Caused by repeated injuries to the head, CTE is linked to contact sports and has been especially prevalent among NFL players and women\u2019s soccer players. During head injuries, nerve axons become damaged, hindering cell-to-cell communication and causing the cells in the brain to waste away.\u00a0<\/span><\/p>\n Cannabinoids can be used to reduce the oxidative stress following head injuries and reduce the swelling that results in the brain. Currently, CTE can only be diagnosed in post-mortem examinations of the brain, making it difficult to determine a population of CTE sufferers. Studies showed the overall prevalence of CTE in football players at\u00a0<\/span>3.7%<\/span><\/a>\u00a0of the total population. Kannalife\u2122 is exploring preventative as well as post-diagnosis solutions for CTE based on cannabinoids.\u00a0<\/span><\/p>\n The company\u2019s newest efforts are aimed at developing a treatment for chemotherapy induced peripheral neuropathy (CIPN). CIPN occurs because chemotherapy and other cancer treatments can cause damage to the nerves away from the brain and spinal cord, with symptoms including tingling in the extremities, burning pain, decreased sensation, and increased sensitivity to touch, temperature, and more. In some cases, nerve damage can be permanent.\u00a0<\/span><\/p>\n No medication or supplement has been shown to definitively prevent CIPN, and it can be disabling side effect of cancer treatment. The global market for the treatment of symptoms associated with CIPN is expected to hit\u00a0<\/span>$1.88 bill by 2024<\/span><\/a>. Kannalife is targeting clinical trials for KLS-13019, its proprietary CBD-like molecule, as a therapeutic for CIPN to begin in Q2 2020.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” custom_padding=”2px||3px|||” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” background_color=”#21b494″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” header_2_font=”|800|||||||” header_2_text_color=”#FFFFFF” header_2_font_size=”34px” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n Our Website:<\/span><\/p>\nMARK CORRAO \u2013 CHIEF FINANCIAL OFFICER<\/strong><\/h3>\n
AREAS OF FOCUS<\/h2>\n
HEPATIC ENCEPHALOPATHY<\/strong><\/h3>\n
CHRONIC TRAUMATIC ENCEPHALOPATHY<\/strong><\/h3>\n
CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY<\/strong><\/h3>\n
CONTACT<\/h2>\n